- Home
- Automated
- List of product information
- LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01% [SIN14365P]
LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01% [SIN14365P]
Active ingredients: LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01%
Last updated 26 October 2025
Product Info
LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01%
[SIN14365P]
Product information
Active Ingredient and Strength | BIMATOPROST - 0.01% W/V |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | ALLERGAN PHARMACEUTICALS IRELAND - IRELAND |
Registration Number | SIN14365P |
Licence Holder | ABBVIE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01EE03 |
1 INDICATIONS AND USAGE
LUMIGAN® 0.01% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
2 DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. LUMIGAN® 0.01% (bimatoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
LUMIGAN® 0.01% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
4 CONTRAINDICATIONS
LUMIGAN® 0.01% is contraindicated in patients with clinically significant hypersensitivity to bimatoprost or to any of the excipients.